Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer

43

GUILFORD, Conn.–(BUSINESS WIRE)–BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that its board of directors has appointed Dr. Deborah A. Rathjen as president and chief http://www.businesswire.com/news/home/20190311005845/en/Bioasis-Appoints-Dr.-Deborah-Rathjen-President-Chief/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==